Literature DB >> 28127707

Stability and Pharmacological Effects of Gene-Recombinant Wild Type and Mutant Human Adrenocorticotropic Hormone.

Yonglin Huang1, Yechun Pei1, Huai Guan1, Shuangshuang Wei1, Hao Wu1, Yuan Zhou1,2, Jinli Pei1, Lintao Chen1, Yuerong Wang1, Yibo Chen1, Qian Han1, Daming Wang3, Dayong Wang4.   

Abstract

PURPOSE: Adrenocorticotropic hormone (ACTH) is the only medicine for treating infantile spasms, however, it is catabolized rapidly. In order to make an ACTH derivative with prolonged effects, we prepared genetically engineered wild type (WT) and mutant ACTH candidates based on protease database analysis, and compared their stability and pharmacological effects.
METHODS: For analysis of stability, serum concentration of WT and mutant ACTH candidates were tested at different time after intravenous injection, and elimination curves were calculated to compare pharmacokinetic properties of WT and E5D-mutant ACTH. For comparison of their pharmacological effects, levels of glucocorticoids (GC) in the blood serum and secreted from cultured Y1 mouse adrenal cells were tested, and their effects on the signaling pathway mediating the expression of genes critical for GC synthesis were analyzed. The effects of ACTHs on transcription levels of the genes involved in GC synthesis were tested by qPCR.
RESULTS: The blood concentration of E5D ACTH is higher than the WT after injection, and E5D mutation increased the t1/2 and AUC of ACTH. Pharmacological experiments showed that the effects of E5D and Y2S mutant ACTH on the production of GC and the critical signal transduction were equivalent to those of WT. WT, E5D and Y2S ACTH also have similar effects on the transcriptional levels of the genes for GC synthesis, including STAR, P450-scc, 3β-HSD, and SF-1.
CONCLUSION: The stability of E5D mutant ACTH is higher than WT ACTH. The pharmacological effects of E5D ACTH is equivalent to those of WT ACTH.

Entities:  

Keywords:  adrenocorticotropic hormone; gene recombinant; long-lasting ACTH; pharmacological effects; stability

Mesh:

Substances:

Year:  2017        PMID: 28127707     DOI: 10.1007/s11095-017-2107-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

Review 1.  CHEMISTRY AND METABOLIC ACTION OF NONSTEROID HORMONES.

Authors:  R SCHWYZER
Journal:  Annu Rev Biochem       Date:  1964       Impact factor: 23.643

Review 2.  Arrestins in the cardiovascular system.

Authors:  Anastasios Lymperopoulos; Ashley Bathgate
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 3.  Arrestin pathways as drug targets.

Authors:  Louis M Luttrell
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 4.  Synaptic changes induced by melanocortin signalling.

Authors:  Vanni Caruso; Malin C Lagerström; Pawel K Olszewski; Robert Fredriksson; Helgi B Schiöth
Journal:  Nat Rev Neurosci       Date:  2014-02       Impact factor: 34.870

Review 5.  A genetic and molecular update on adrenocortical causes of Cushing syndrome.

Authors:  Maya Lodish; Constantine A Stratakis
Journal:  Nat Rev Endocrinol       Date:  2016-03-11       Impact factor: 43.330

Review 6.  Using the human melanocortin-2 receptor as a model for analyzing hormone/receptor interactions between a mammalian MC2 receptor and ACTH(1-24).

Authors:  Liang Liang; Joseph K Angleson; Robert M Dores
Journal:  Gen Comp Endocrinol       Date:  2012-11-29       Impact factor: 2.822

7.  Molecular Mechanism of Isocupressic Acid Supresses MA-10 Cell Steroidogenesis.

Authors:  Kuan-Hao Tsui; Jyun-Yuan Wang; Leang-Shin Wu; Chih-Hsien Chiu
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-15       Impact factor: 2.629

Review 8.  Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences.

Authors:  K-H Chang; C E Ercole; N Sharifi
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

9.  SF-1 (NR5A1) expression is stimulated by the PKA pathway and is essential for the PKA-induced activation of LIPE expression in Y-1 cells.

Authors:  K Kulcenty; M Holysz; W H Trzeciak
Journal:  Mol Cell Biochem       Date:  2015-06-30       Impact factor: 3.396

10.  Distinct melanocortin 2 receptor accessory protein domains are required for melanocortin 2 receptor interaction and promotion of receptor trafficking.

Authors:  Tom R Webb; Li Chan; Sadani N Cooray; Michael E Cheetham; J Paul Chapple; Adrian J L Clark
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.